Brentuximab Vedotin Plus AVD in Non-bulky Limited Stage Hodgkin Lymphoma
Phase of Trial: Phase II
Latest Information Update: 22 Feb 2018
At a glance
- Drugs Brentuximab vedotin (Primary) ; Dacarbazine; Doxorubicin; Vinblastine
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 23 Jan 2018 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 08 May 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.